| Literature DB >> 22683416 |
Felix Olasagasti1, Juan Carlos Ruiz de Gordoa.
Abstract
The field of point-of-care (POC) testing technology is developing quickly and producing instruments that are increasingly reliable, while their size is being gradually reduced. Proteins are a common target for POC analyses and the detection of protein markers typically involves immunoassays aimed at detecting different groups of proteins such as tumor markers, inflammation proteins, and cardiac markers; but other techniques can also be used to analyze plasma proteins. In the case of nucleic acids, hybridization and amplification strategies can be used to record electromagnetic or electric signals. These techniques allow for the identification of specific viral or bacterial infections as well as specific cancers. In this review, we consider some of the latest advances in the analysis of specific nucleic acid and protein biomarkers, taking into account their trend toward miniaturization and paying special attention to the technology that can be implemented in future applications, such as lab-on-a-chip instruments.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22683416 PMCID: PMC7104926 DOI: 10.1016/j.trsl.2012.02.012
Source DB: PubMed Journal: Transl Res ISSN: 1878-1810 Impact factor: 7.012
Summary of the latest works integrating different POC instruments to measure protein concentrations
| Tested target | Relevance of sample | Detection strategy | Sensitivity/Limit of detection (LOD) | Timeframe | Ref. |
|---|---|---|---|---|---|
| Lateral flow immunoassays | |||||
| Thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (hCG) | Whole blood and plasma | Piezofilm sensor | LOD: 18 pg/mL for TSH | 5–10 min | |
| C reactive protein (CRP) | Whole blood | Fluorescence (in plastic disposable cartridge) | LOD: 133 ng/mL | 10 min | |
| Biotoxins ricin, Shiga toxin I and Staphylococcal enterotoxin B | Biological toxins | Fluorescence (Microfluidic with polyacrylamide electrophoresis) | LOD: 20 nM for ricin; | Incubation Ag-Ab: 30 min | |
| Matrix metalloproteinase-8 (MMP-8) | Saliva | Fluorescence (Microfluidic with polyacrylamide electrophoresis) | LOD: 130 ng/mL | 2 min | |
| CRP | Serum | Chemiluminescence (Microfluidic channels) | Linear range: 2–15 μg/mL | 26 min | |
| CRP | Serum and cerebrospinal fluid | Fluorescence (Microfluidic capillary system for immunoaffinity chromatography) | Calibration ranges: | 10 min | |
| CRP | Serum | Fluorescence (Microfluidic on PDMS) | LOD: 10 ng/mL | <3 min | |
| CRP | CRP-enriched human serum | Fluorescence (Microfluidic on PDMS) | LOD: 0.42 nM | 20 min | |
| Vascular endothelial growth factor (VEGF) | Human plasma | Fluorescence (Elastomeric microfluidic chip) | LOD: 4 pM | ∼10 min | |
| CRP and ferritin | Serum | Fluorescence (Elastomeric microfluidic chip) | LOD: 12 μg/mL for CRP | ||
| CRP, tumor necrosis factor α (TNFα), and procalcitonin (PCT) | Serum | Fluorescence (Sensor chip of PMMA) | LOD: 1.265 μg/mL for CRP | 25 min approximately | |
| Prostate specific antigen (PSA) | Serum | Voltammetry (Electrochemical inmunosensor in plastic disposable cartridge) | LOD: 20 pg/mL | 20 min | |
| Cardiac troponin I (cTnI) | Serum | Magnetic signal (plastic disposable cartridge) | LOD: 10 pg/mL | 15 min | |
| Microarrays (multiplex) | |||||
| CRP, interleukin 6 (IL-6) and PCT | Plasma | Microfluidic fluorescence | LOD: 0.35 ng/mL for CRP | 35 min | |
| 12 tumor markers (PSA and 11 cytokines) | Plasma | Fluorescence | LOD: ∼30pM | 10 min | |
| PSA, TNFα, IL-6, and IL-23 | Protein solutions | Bright white “light-emitting diode” (LED) | 3.4 ng/mL for PSA | ||
| Tumor markers (cancer antigens CA 153, CA 125, CA199, and carcinoembryonic antigen: CEA) | Serum | Voltammetry (Electrochemical inmunosensor) | Detectable linear ranges: | <5 min | |
| Anti-hepatitis C virus (anti-HCV) antibodies (HCV core and nonstructural 4 antigen [NS4]) | Artificial targets and human serum | Fluorescence | LOD: 10 ng/mL for anti-CHV core | 14 min | |
| CRP | Saliva (1000-fold dilution) | Fluorescence | LOD: 10 pg/mL | 10 min | |
| 10 cytokines | Saliva | Fluorescence | LOD: From 8 pM for IL-8 to 469 pM for (VEGF) | Incubation: 2 h | |
| Other methods | |||||
| Cardiac troponin T (cTnT) | Serum | Amperometric (Electrochemical inmunosensor) | LOD: 0.2 ng/mL | 2 h | |
| Tumor markers (PSA, CEA, and AFP) | Serum | Multiplexed silicon field-transistor (Si-FET) | Detection quantitative: from 0.2 to 114 ng/mL | 20 min | |
| PSA and PSA-α 1-antichymotrypsin | Serum | Quartz crystal microbalance e sensor | LOD: 0.39 ng/mL | 8 min | |
| CRP | Whole blood | Magnetic permeability inmunoassay | LOD: 3 μg/mL | 5.5 min | |
| CRP | Whole Blood | Noncompetitive immunoassay | LOD: 160 ng/mL | 2 min | |
| PSA | Serum | Homogeneous fluoroimmunoassay | LOD: 56 pg/mL | 30 min | |
| No antibodies | |||||
| Thrombin | Plasma | GoldBio strip reader after aptamers binding | LOD: 2.5 nM | 10 min | |
| Generation of thrombin and other coagulation activators | Whole blood and plasma | Amperometric (Substrate cleaved for coagulation activators) | LOD: 0.4 U/mL thrombin | 15–20 min | |
| Albumin | Urine | Visual (Spot test with erythrosin B) | LOD: 0.5 mg/mL | 5 min | |
| Albumin | Urine | Reflectance (Test strip) | LOD: 10 μg/mL | 1 min | |
| α-amilase | Saliva | Reflectance with LED device (Test strip) | Linear range: 10–132 kU/L at 37°C | 0.5 min | |
We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample.
Some studies focus on LOD and others on sensitivity. In either case, the values may depend on specific experimental conditions, and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters.
Summary of the latest works integrating different POC instruments to analyze nucleic acids‡
| Tested target | Relevance of sample | Detection strategy | Sensitivity /Limit of detection (LOD) | Timeframe | Ref. |
|---|---|---|---|---|---|
| IL-8 mRNA (proposed salivary marker for oral cancer) | Clinical saliva samples | Signal amplification taking advantage of steric self-hindrance of a hairpin probe that prevents horseradish peroxidase to reach its substrate and produce and electrochemical signal | LOD: 0.4 fM | 1 min | |
| Methicillin resistant | Swab collected sample | Loop-mediated isothermal amplification (LAMP) and colorimetry | LOD: 17 copies in 100 μL of reaction volume | ∼90 min | |
| Nervous necrosis virus RNA | Infected biological samples | Magnetic purification, reverse-transcript LAMP (RT-LAMP) and slab gel electrophoresis | LOD: 100 fg cDNA | 60 min | |
| Flu viruses including influenza A H1N1 | Clinical samples | Visual and fluorimetric detection on multiplex microfluidic LAMP (mμ-LAMP) with 10 microchambers | LOD: 10 copies/ μL in 2 μL | 0.5 h | |
| Genomic DNA of | Laboratory preparations of | Fluorescence after helicase dependent amplification (HAD) at 65°C | LOD: 250 pg genomic | ∼145 min | |
| RNA from | RNA purified from a laboratory strain | Lateral flow microarray (LFM) after nucleic acid sequence based amplification (NASBA) | LOD: 250 fg (2–3 | ∼60 min | |
| Purified total mRNA from | Oligonucleotide-gold nanoparticles after amplification of heat shock proteins (HSP) | LOD: 5000 | ∼2–3 h | ||
| pUC18 | pUC18 amplicon | Sanger sequencing | LOD: 1 fmole of DNA template | ∼30–35 min | |
| Single nucleotide variations/interaction of DNA with polymerase | Synthetic oligonucleotides | Nanopore analysis | LOD: 100 fmole | ∼5 min | |
We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample.
Some studies focus on LOD and others on sensitivity. In either case, the values may depend on specific experimental conditions and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters.
See Table III for PCR applications.
Summary of the latest works integrating different steps in the sample preparation, PCR-amplification, and detection of biological samples on solid supports as a step toward the fabrication of versatile POC instruments
| Tested target | Relevance of sample | Sensor | Device features | Sensitivity/Limit of detection (LOD) | Timeframe | Ref. |
|---|---|---|---|---|---|---|
| Cyanobacterial 16S rRNA gene (2060-bp) and human anti-α-1-chymotrypsin gene (330-bp) | Test oligos | Off the device | PCR only | LOD: 0.5 ng/μL genomic DNA | 22.5 min (for amplification only) | |
| H1N1 virus | Swab saliva sample | E-DNA | MIMED | LOD:10 TCID50 | 3.5 h (PCR∼150min) | |
| Influenza A, influenza B, corona virus OC43, and human metapneumovirus | Cloned target viral sequences in plasmid standards | Fluorescence labeling of forward PCR primers | Integrated microdevice for concentration, amplification and multiplex analysis | LOD: 10 copies/reactor | within 2 h | |
| STR | Cells from a buccal swab sample | optical excitation/ detection module | DNA analysis compatible with CODIS | Sensitivity: 1.15bp | 3.5 h | |
| STR (Y STR ie, STR from the Y chromosome) | Buccal swab sample | Fluorescence from fluorescence-labeled primers | Just for stacking capillary electrophoresis (no PCR) | LOD: 25 pg (1:1000 male:female genomic DNA + 15 min. DNase I digestion) | 6 min just the electrophoresis | |
| STR | Biological stains from a mock crime scene | Fluorescence | Real-time PCR in 100mm wafers | LOD: 100 copies for complete DNA profile; sensitivity: 0.8 bp allele typing accuracy | 2.5 h | |
| Determination of monozygous twinning | Bucal swab sample | Fluorescence | microfabricated capillary array electrophoresis (μCAE) | Sensitivity: single base resolution | <30 min | |
| Lab culture | Fluorescence reporter probes | Miniature real-time PCR | Minimum amount used: 1.25 ng/μL | Regular real-time PCR | ||
| Synthetic test oligo | Synthetic test oligo | Fluorescence of Cy3-labeled probe | Microstructured optical fiber (MOF) | 10 μM (in 10 nL) | <30 min (hybridize and detect) | |
| Methicillin-resistant | DNA extracted from clinical MRSA isolates | FRET from probes labeled with AlexaFluor 647 reporter dye and BHQ3 quencher dye | PDMS microfluidic system for PCR and fluorescence detection | Used sample containing 11.2 pg of DNA | Regular real-time PCR | |
| λDNA | In test buffer | FRET from fluorescein and MGB-NFQ maker-containing primers | Microfluidic device to characterize PCR in aqueous-in-oil droplets and FRET | Minimum used concentration: 3.5 × 10−4ng/μL | Regular real-time PCR | |
| Lab culture | Electrochemical detection on gold nanoparticles | Thermal lysis, magnetic isolation, asymmetric PCR (one primer more abundant than the other), and detection using silver-enhanced gold nanoparticles | LOD: 0.5 nM genomic DNA; linear between 102–105 cells/sample | About 3 h | ||
| Genetic breast cancer markers: estrogen receptor-α, plasminogen activator urokinase receptor, epidermal growth factor receptor, and erythroblastic leukemia viral oncogene homolog 2 | Test samples | Surface Plasmon Resonance | Multiplex device | LOD: ∼3 nM | 90 min (excluding PCR) | |
| Hepatitis C virus RNA | Total RNA extracted from clinical samples | Cy3-conjugated oligonucleotide detection probes | Microarray combining protein and nucleic acid detection | LOD: 10 pM | 16 min after PCR | |
We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample.
Some studies focus on LOD and others on Sensitivity. In either case, the values may depend on specific experimental conditions and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters.
Short tandem repeats (STR) can be used for identification in forensic science, a field that could also benefit from new POC applications.